Composition of leukotrienes antagonist oral liquid

Abstract

The invention relates to an oral liquid of leukotriene antagonist against allergy, inflammation, asthma that can be used as cell protecting agent, comprising at least a buffer solution and Montelukast dissolved in the buffer solution and its pharmaceutically acceptable salts. The pH of the buffer solution is between 7-11, and the buffer solution includes at least water, pharmaceutically acceptable alcohols, buffering agents and pharmaceutically acceptable additives.

Description

technical field [0001] The invention relates to a composition of an antiallergic oral liquid, in particular to a composition of an oral liquid of a leukotriene antagonist and inhibitor. Background technique [0002] In recent years, the number of patients with allergic diseases has increased significantly, such as hay fever, allergic rhinitis, urticaria, and asthma. The types, symptoms, and degrees of allergic diseases vary widely. Taking asthma as an example, there are currently about 150,000,000 asthmatics in the world, and the number of deaths due to asthma is about 200,000 each year, and the global asthmatics are growing at a rate of 20-50% per decade. Increase, the medical expenses spent on such chronic diseases are quite huge. Every year, the United States spends about 6 billion U.S. dollars on asthma medical expenses, Germany 3 billion U.S. dollars, the United Kingdom 1.6 billion U.S. dollars, and about 2 billion Taiwan dollars in this country. , of which the annual ...

AI Technical Summary

Problems solved by technology

However, the use of lozenges is very inconvenient for asthmatic children, especially children with asthma under 6 years old or elderly asthmatics. Difficulty swallowing, so must be given as a powder

Images